Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.67 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.64 |
| ▸ | FEN1 | P39748 | 1/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204218 | 0.92 | GSK3B (0.70) | GSK3BPTPN1ERCC5FEN1MMP1 | |
| SCHEMBL5801716 | 0.87 | SRD5A2 (0.53) | GSK3BPTPN1ERCC5FEN1MMP1 | |
| SCHEMBL203505 | 0.86 | TNKS (0.58) | GSK3BPTPN1ERCC5FEN1PARP10 | |
| SCHEMBL4456868 | 0.85 | NR4A1 (0.64) | GSK3BPTPN1PARP10SRD5A2SMN1; SMN2 | |
| SCHEMBL8260473 | 0.85 | GSK3B (0.77) | GSK3BPTPN1ERCC5FEN1MMP1 | |
| SCHEMBL9814634 | 0.84 | MMP1 (0.77) | ERCC5FEN1MMP1PARP10SRD5A2 | |
| SCHEMBL5312318 | 0.84 | ERCC5 (0.67) | GSK3BPTPN1ERCC5FEN1PARP10 | |
| SCHEMBL3366230 | 0.83 | PTPN1 (0.78) | GSK3BPTPN1ERCC5FEN1PARP10 | |
| SCHEMBL10145026 | 0.83 | GSK3B (0.59) | GSK3BPTPN1ERCC5FEN1MMP1 | |
| SCHEMBL2773360 | 0.83 | GSK3B (0.89) | GSK3BPTPN1MMP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2325178-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | DAISO CO., LTD. (JP) | 2011-05-25 | — | — | EP | claimed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| EP-3846793-B1 | EIF4E INHIBITORS AND USES THEREOF | PIC THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| CN-112313229-A | Substituted aminothiazoles as inhibitors of nucleases | 马萨里克大学 | 2021-02-02 | — | — | CN | disclosed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0379145-B1 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID CO (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
| EP-0397175-A1 | Substituted pyrrolizine compounds and theit use as pharmaceuticals | Dannhardt, Gerd, Prof.Dr. (DE) | 1990-11-14 | — | — | EP | disclosed |
| US-4968702-A | ANTIARTHRITIC, INHIBITORS OF PROGRESSIVE JOINT DETERIORATION, IMMUNOSUPPRESSANT | AMERICAN CYANAMID COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0379145-A2 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | GSK3B 890/4885PTPN1 1527/4885ERCC5 3687/4885 |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | GSK3B 3281/4885PTPN1 3966/4885ERCC5 277/4885 |
| US-20110288315-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUND | CYP51A1, KMO, TALDO1 | GSK3B 776/4885PTPN1 4327/4885ERCC5 4661/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | GSK3B 890/4885PTPN1 1527/4885ERCC5 3687/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | GSK3B 890/4885PTPN1 1527/4885ERCC5 3687/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | GSK3B 3281/4885PTPN1 3966/4885ERCC5 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.